Arrowhead FQ2 top line down 51%; COVID-19 program started

Arrowhead Pharmaceuticals (NASDAQ:ARWR) fiscal Q2 results:

Revenue: $23.5M (-51.1%).

Net loss: ($19.8M); loss/share: ($0.20).

Development program in COVID-19 underway (no additional details disclosed).

Arrowhead Pharmaceuticals EPS misses by $0.09, beats on revenue

https://seekingalpha.com/news/3571471-arrowhead-fq2-top-line-down-51-covidminus-19-program-started